Phase III results offer Amgen hope for possible Sensipar replacement

11 January 2017

Amgen (Nasdaq: AMGN) has published results from three Phase III studies of Parsabiv (etelcalcetide), the company’s nephrology product candidate.

The results are important, as the investigational compound is a potential successor to the American biotech’s blockbuster Sensipar (cinacalcet), a multi-billion dollar revenue product which is due to lose patent protection in 2018.

Like Sensipar, Parsabiv is designed to treat secondary hyperparathyroidism (sHPT), a chronic and serious condition that is often progressive among patients with chronic kidney disease and is associated with significant clinical consequences.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK